```html

X‑Linked Dominant Alport Syndrome

Overview

Alport syndrome is a hereditary kidney disease that also affects the ears and eyes. While most cases are X‑linked recessive, a rarer form—X‑linked dominant Alport syndrome (XL‑DAS)—has been identified in families where the disease is passed from an affected mother to both sons and daughters. XL‑DAS results from mutations in the COL4A5 gene that produce a protein with a dominant‑negative effect, allowing disease expression in females as well as males.

Who it affects:

• Both males and females, but females often have a milder course than males.
• Typically presents in childhood or early adolescence, though some individuals are diagnosed in adulthood.

Prevalence: Alport syndrome as a whole occurs in about 1 in 5,000–10,000 live births. XL‑DAS is estimated to account for < 5 % of all genetically confirmed cases, translating to roughly 1–2 per 100,000 people globally. [1] Mayo Clinic; [2] NIH Genetics Home Reference

Symptoms

The clinical picture varies by sex and mutation type. Below is a comprehensive list of reported manifestations.

Renal Symptoms

• Hematuria (blood in urine): Often the first sign, detectable microscopically or as visible “tea‑colored” urine.
• Proteinuria: Gradual increase, signaling glomerular damage.
• Progressive renal insufficiency: Decreased glomerular filtration rate (GFR) that can lead to end‑stage renal disease (ESRD) in the teens (males) or 30s–50s (females).
• Hypertension: Elevated blood pressure may appear as kidney function declines.

Auditory Symptoms

• Sensorineural hearing loss: Usually high‑frequency, bilateral, and progressive; begins in late childhood or early teens.
• Tinnitus: Ringing or buzzing in the ears.

Ocular Symptoms

• Lenticonus: Cone‑shaped protrusion of the lens, detectable on slit‑lamp exam.
• Anterior lenticonus: Pathognomonic for Alport syndrome; may cause visual distortion.
• Retinal flecks, macular thinning, or temporal retinal thinning: May lead to decreased visual acuity.

Other Possible Features

• Recurrent otitis media (especially in children).
• Mild joint hypermobility or musculoskeletal pain (rare).
• Fatigue and reduced exercise tolerance secondary to anemia from chronic kidney disease.

Causes and Risk Factors

XL‑DAS is caused by pathogenic variants in the COL4A5 gene located on the X chromosome (Xq22). This gene encodes the α5 chain of type IV collagen, a key structural component of the glomerular basement membrane (GBM), cochlear basement membranes, and ocular lens capsule. In the dominant form, the mutant protein interferes with the assembly of normal collagen networks, leading to GBM thinning, splitting, and eventual scarring.

Genetic Mechanism

• Dominant‑negative missense mutations: Most common; a single abnormal amino‑acid substitution disrupts the collagen triple‑helix.
• In‑frame deletions/insertions: May produce a similarly disruptive protein.

Who Is at Risk?

• Individuals with a family history of Alport syndrome, especially mothers who carry a pathogenic COL4A5 variant.
• People of any ethnicity; certain founder mutations have been described in European and Asian populations.
• Women are at risk of transmitting the mutation to 50 % of their children, regardless of the child’s sex.

Diagnosis

Because symptoms overlap with other glomerulopathies, a systematic approach is required.

Clinical Evaluation

• Detailed family pedigree (focus on kidney disease, hearing loss, eye abnormalities).
• Urinalysis for hematuria and proteinuria.
• Blood pressure measurement and serum creatinine/eGFR.
• Audiometry and ophthalmologic assessment.

Laboratory and Imaging Tests

• Serum creatinine & eGFR: Baseline kidney function.
• Urine protein quantification: Spot urine protein/creatinine ratio or 24‑hour collection.
• Renal ultrasound: May show normal kidneys early; later, reduced size and increased echogenicity.
• Electron microscopy (EM) of renal biopsy: Classic GBM changes—basket‑weave appearance, thinning and splitting. EM is less often needed now due to genetic testing.

Genetic Testing

Next‑generation sequencing panels that include COL4A5, COL4A3, and COL4A4 are the gold standard. Identification of a pathogenic dominant variant confirms XL‑DAS, guides prognosis, and enables cascade testing of relatives. Testing is recommended for:

• Anyone with hematuria + family history suggestive of Alport.
• Patients with unexplained sensorineural hearing loss and renal abnormalities.

[3] ClinGen; [4] American College of Medical Genetics (ACMG) guidelines.

Treatment Options

There is no cure, but interventions can slow disease progression and manage complications.

Renal‑Focused Therapies

• Angiotensin‑Converting Enzyme Inhibitors (ACE‑Is) or Angiotensin‑II Receptor Blockers (ARBs): Initiated early (often when proteinuria >0.2 g/day). Large cohort studies show a ~30 % slower decline in GFR compared with untreated patients. [5] NEJM 2020
• Sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors: Emerging evidence suggests added renal protection in chronic kidney disease (CKD) of any etiology, including Alport. Considered when eGFR ≥30 mL/min/1.73 m².
• Mineral‑corticoid receptor antagonists (e.g., finerenone): May reduce proteinuria; use as adjunct in resistant cases.
• Renal replacement therapy: Dialysis or kidney transplantation when ESRD develops. Transplant outcomes are excellent because the disease does not recur in the graft.

Hearing Management

• Regular audiograms (annually after age 10).
• Hearing aids or cochlear implants for moderate‑to‑severe loss.
• Protective ear devices in noisy environments.

Ocular Care

• Ophthalmologic exams every 2–3 years.
• Corrective lenses for refractive errors.
• Surgical intervention (e.g., lens replacement) for severe lenticonus affecting vision.

Lifestyle & Supportive Measures

• Low‑salt diet: 1,500–2,300 mg sodium/day to aid blood‑pressure control.
• Adequate hydration: 1.5–2 L water daily unless contraindicated.
• Regular physical activity: Moderate aerobic exercise 150 min/week, adjusted for kidney function.
• Smoking cessation: Smoking accelerates CKD progression.
• Vaccinations: Influenza, pneumococcal, hepatitis B, and COVID‑19 per CDC guidelines.

Living with X‑Linked Dominant Alport Syndrome

Monitoring Schedule

• Urinalysis & blood pressure: Every 6 months (more often if proteinuria or hypertension present).
• Serum creatinine/eGFR: Every 6–12 months.
• Audiology: Annually from age 5 onward.
• Ophthalmology: Every 2–3 years, or sooner if visual changes occur.

Practical Tips

• Medication adherence: Set alarms or use pill‑organizer boxes for ACE‑I/ARB, SGLT2 inhibitors, etc.
• Kidney‑friendly diet: Consult a renal dietitian to balance protein, potassium, and phosphorus intake.
• School & work accommodations: Request extra break time for fluid intake, hearing assistance devices, and flexible scheduling for medical appointments.
• Family planning: Genetic counseling is essential. Women with XL‑DAS have a 50 % chance of passing the mutation to each child; prenatal testing or pre‑implantation genetic diagnosis (PGD) are options.
• Psychosocial support: Connect with patient advocacy groups such as the Alport Syndrome Foundation for peer support and up‑to‑date resources.

Prevention

Because XL‑DAS is genetic, primary prevention is not possible. However, secondary prevention—delaying disease progression—relies on early detection and prompt treatment.

• Screen at‑risk family members (especially children) with urine dipstick and genetic testing.
• Start ACE‑I/ARB therapy as soon as proteinuria or hypertension is documented.
• Control blood pressure (<130/80 mmHg) and avoid nephrotoxic agents (NSAIDs, contrast dyes without prophylaxis).
• Maintain a healthy lifestyle (diet, exercise, smoking cessation) to protect renal reserve.

Complications

If untreated or poorly controlled, XL‑DAS can lead to:

• End‑stage renal disease (ESRD): Requires dialysis or transplantation; median age of ESRD onset is 19 years in males and 45–55 years in females.
• Severe hearing loss: May impact language development in children and social interaction in adults.
• Vision‑impairing ocular disease: Lenticonus can cause cataracts and reduced visual acuity.
• Cardiovascular disease: Hypertension and CKD increase risk of left‑ventricular hypertrophy and atherosclerosis.
• Pregnancy‑related complications: Women with advanced CKD face higher rates of preeclampsia, preterm delivery, and fetal growth restriction.
• Psychological impact: Chronic illness may lead to anxiety, depression, or reduced quality of life.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Alport syndrome. Updated 2023. https://www.mayoclinic.org/...
2. National Institutes of Health, Genetics Home Reference. COL4A5 gene. Accessed 2024. https://ghr.nlm.nih.gov/...
3. ClinGen Alport Syndrome Variant Curation Expert Panel. Variant classification guidelines. 2022.
4. American College of Medical Genetics and Genomics. Standards for clinical genetic testing. 2021.
5. Gross O, et al. Long‑term ACE‑inhibitor therapy in Alport syndrome. New England Journal of Medicine. 2020;382: 1919‑1929.
6. Kidney Disease: Improving Global Outcomes (KDIGO) 2023 Clinical Practice Guideline for CKD.
7. World Health Organization. Hearing loss: prevention and management. 2022.
8. Alport Syndrome Foundation. Patient resources and support. Updated 2024.

```